Volume 10 Issue 3
May  2019
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2019  >  10(3): 308-312
Lin Guozhen, Dai Tianxing, Liu Rongqiang, et al. Effect of different liver function Child-Pugh classification on clinical prognosis of hepatocellular carcinoma recipients after liver transplantation[J]. ORGAN TRANSPLANTATION, 2019, 10(3): 308-312. doi: 10.3969/j.issn.1674-7445.2019.03.014
Citation: Lin Guozhen, Dai Tianxing, Liu Rongqiang, et al. Effect of different liver function Child-Pugh classification on clinical prognosis of hepatocellular carcinoma recipients after liver transplantation[J]. ORGAN TRANSPLANTATION, 2019, 10(3): 308-312. doi: 10.3969/j.issn.1674-7445.2019.03.014
shu

Effect of different liver function Child-Pugh classification on clinical prognosis of hepatocellular carcinoma recipients after liver transplantation

doi: 10.3969/j.issn.1674-7445.2019.03.014

  • Department of Hepatic Surgery, Liver Transplantation Center, the Third Affliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

More Information
  • Corresponding author: Wang Guoying, Email: wanggy3@126.com
  • Received Date: 2019-01-25
    Available Online: 2021-01-19
  • Publish Date: 2019-05-15
    Abstract
  •   Objective  To evaluate the effect of the different Child-Pugh classification on the recurrence and survival of hepatocellular carcinoma (HCC) recipients after liver transplantation.  Methods  Clinical data of 125 HCC recipients undergoing liver transplantation were retrospectively analyzed. The 3-year disease-free survival (DFS) and overall survival (OS) rates were calculated by Kaplan-Meier survival curve. The independent risk factors probably affecting the recurrence and survival of HCC recipients after liver transplantation were identified by using Cox's proportional hazards regression model.  Results  The median follow-up time was 25.6 months. The 3-year DFS and OS rates were 68.4% and 65.7% for all patients. The 3-year DFS and OS rates in 113 patients with Child-Pugh class A/B HCC were 68.6% and 66.2%, whereas 66.7% and 65.6% for 12 patients with Child-Pugh class C HCC with no statistical significance (all P>0.05). Cox's proportional hazards regression model demonstrated that vascular invasion (P=0.001)and the number of tumors>3 (P=0.025) were the independent risk factors for the postoperative recurrence of HCC in recipients undergoing liver transplantation. Alpha fetoprotein (AFP)>400μg/L (P=0.035), vascular invasion (P=0.031) and number of tumors>3 (P=0.008) were the independent risk factors affecting the survival of HCC patients.  Conclusions  The postoperative prognosis does not significantly differ between Child-Pugh class C and A/B HCC patients after liver transplantation. AFP, vascular invasion and number of tumors are the risk factors affecting the clinical prognosis of HCC patients after liver transplantation. Liver transplantation is an efficacious treatment for HCC patients with Child-Pugh class C.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. DOI: 10.3322/caac.21492.
    [2]
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019.
    [3]
    European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4):908-943. DOI: 10.1016/j.jhep.2011.12.001.
    [4]
    HEIMBACH JK, KULIK LM, FINN RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1):358-380. DOI: 10.1002/hep.29086.
    [5]
    中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肿瘤学杂志, 2011, 16(10):929-946. DOI: 10.3969/j.issn.1009-0460.2011.10.017.

    Ministry of Health of the People' s Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (2011 edition)[J]. Chin Clin Oncol, 2011, 16(10):929-946. DOI: 10.3969/j.issn.1009-0460.2011.10.017.
    [6]
    XIE DY, REN ZG, ZHOU J, et al. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma[J]. Hepatobiliary Surg Nutr, 2017, 6(6):387-396. DOI: 10.21037/hbsn.2017.11.01.
    [7]
    SANGIOVANNI A, COLOMBO M. Treatment of hepatocellular carcinoma: beyond international guidelines[J]. Liver Int, 2016, 36 (Suppl 1):124-129. DOI: 10.1111/liv.13028.
    [8]
    VERSLYPE C, ROSMORDUC O, ROUGIER P, et al. Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2012, 23(Suppl 7):vii41-vii48. http://d.old.wanfangdata.com.cn/Periodical/lcgdbzz201904013
    [9]
    BRUIX J, SHERMAN M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53(3):1020-1022. DOI: 10.1002/hep.24199.
    [10]
    MANZINI G, HENNE-BRUNS D, PORZSOLT F, et al. Is there a standard for surgical therapy of hepatocellular carcinoma in healthy and cirrhotic liver? a comparison of eight guidelines[J]. BMJ Open Gastroenterol, 2017, 4(1):e000129. DOI: 10.1136/bmjgast-2016-000129.
    [11]
    BENSON AB 3RD, ABRAMS TA, BEN-JOSEF E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers[J]. J Natl Compr Canc Netw, 2009, 7(4):350-391. doi: 10.6004/jnccn.2009.0027
    [12]
    BENSON AB 3RD, D' ANGELICA MI, ABBOTT DE, et al. NCCN guidelines insights: hepatobiliary cancers, version 1.2017[J]. J Natl Compr Canc Netw, 2017, 15(5):563-573. doi: 10.6004/jnccn.2017.0059
    [13]
    TOSO C, MAZZAFERRO V, BRUIX J, et al. Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma[J]. Am J Transplant, 2014, 14(10):2221-2227. DOI: 10.1111/ajt.12923.
    [14]
    OMATA M, LESMANA LA, TATEISHI R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma[J]. Hepatol Int, 2010, 4(2):439-474. DOI: 10.1007/s12072-010-9165-7.
    [15]
    OMATA M, CHENG AL, KOKUDO N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update[J]. Hepatol Int, 2017, 11(4):317-370. DOI: 10.1007/s12072-017-9799-9.
    [16]
    中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范(2017年版)[J].临床肝胆病杂志, 2017, 33(8):1419-1431.DOI: 10.3969/j.issn.1001-5256.2017.08.003.

    National Health and Family Planning Commission of People' s Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (2017 edition) [J]. J Clin Hepatol, 2017, 33(8):1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003.
    [17]
    Korean Liver Cancer Study Group (KLCSG), National Cancer Center, Korea (NCC). 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma[J]. Korean J Radiol, 2015, 16(3):465-522. DOI: 10.3348/kjr.2015.16.3.465.
    [18]
    KOKUDO N, HASEGAWA K, AKAHANE M, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC guidelines)[J]. Hepatol Res, 2015, 45(2). DOI: 10.1111/hepr.12464.
    [19]
    POON RT, CHEUNG TT, KWOK PC, et al. Hong Kong consensus recommendations on the management of hepatocellular carcinoma[J]. Liver Cancer, 2015, 4(1):51-69. DOI: 10.1159/000367728.
    [20]
    LU SN, WANG JH, SU CW, et al. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan[J]. J Formos Med Assoc, 2018, 117(5):381-403. DOI: 10.1016/j.jfma.2017.09.007.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (252) PDF downloads(10) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return